Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Leuk Lymphoma 2019 Dec 16;60(12):2960-2967. Epub 2019 May 16.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48-2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39-2.78) in patients who did not ( = .042), while median overall survival (OS) was 5.70 years (95% CI 3.02-9.00) and 8.43 years (95% CI 6.62-9.17), respectively ( = .030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1613536DOI Listing
December 2019
7 Reads

Publication Analysis

Top Keywords

newly diagnosed
16
diagnosed multiple
8
thrombocytopenia newly
8
treatment-related thrombocytopenia
8
multiple myeloma
8
≥100000/µl median
4
counts ≥100000/µl
4
median progression-free
4
progression-free survival
4
pfs 188 years
4
survival pfs
4
platelet counts
4
prognostic treatment-related
4
receiving proteasome
4
patients receiving
4
proteasome inhibitors
4
and/or immunomodulators
4
pretreatment platelet
4
immunomodulators pretreatment
4
188 years 95%
4

References

(Supplied by CrossRef)

Cox D et al.
J Roy Stat Soc Series B 1972

Similar Publications